ArticlePloS one2025
Neutropenic sepsis and septic shock in ICU patients: A single-center experience over the last decade.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Auricularia auricula's Polysaccharides Confer Protection in Murine Sepsis via Immune Modulation.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSepsis and septic shock in patients with neutropenia are associated with high mortality. We investigated the features and outcome predictors of neutropenic sepsis in the last decade.
methodsConsecutive patients who were admitted to the intensive care unit (ICU) of a French university-affiliated hospital in 2012-2022, met criteria for sepsis or septic shock, and had neutropenia were included retrospectively. Patient features were collected and compared for 2012-2017 and 2018-2022. Factors associated with hospital mortality were sought by univariate and multivariate analyses.
resultsOf the 185 patients, 85 were admitted in 2012-2017 and 100 in 2018-2022. The more recent group was older and had a heavier comorbidity burden but had a hospital mortality rate of 40.0% compared to 49.4% in the early group (p = 0.24). The most common source infections were pulmonary (24.8%) and hepatobiliary or gastrointestinal (23.8%). Gram-negative bacilli predominated. Predictors of in-hospital mortality were older age (odds ratio [OR], 1.04; 1.01-1.07; P = 0.005) and worse SOFA score (OR, 1.22; 1.05-1.42; P = 0.009). Aminoglycoside therapy predicted lower in-hospital mortality regardless of infection site and renal function (OR, 0.30; 0.14-0.63; P = 0.002). Early source-control interventions were not significantly associated with hospital mortality.
conclusionIntensivists are admitting patients with neutropenic sepsis who are older and have more comorbidities than was the case in earlier years. Despite this change, there is a non-statistically significant trend of declining mortality. Our findings support the initiation at ICU admission of combination antibiotic therapy including an aminoglycoside.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.